Response rates, additional therapies after induction, and subsequent outcomes
| . | R-B . | R-CHOP/R-DHAP . | P . |
|---|---|---|---|
| Response rates and additional first line therapies | N = 97 | N = 232 | |
| Response rates after induction, n (%) | |||
| Complete response | 52 (54) | 122/226* (54) | |
| Partial response | 35 (36) | 91/226 (40) | |
| Stable disease | 2 (2) | 5/226 (2) | |
| Progressive disease | 8 (8) | 8/226 (4) | |
| ASCT, n (%) | 75 (77) | 181 (78) | .890 |
| Maintenance rituximab, n (%) | 76 (78) | 4 (2) | <.001 |
| Time-to-event outcomes from start of induction | N = 97 | N = 232 | |
| PFS from start of induction | |||
| Median, years (95% CI) | NR† | 9.5 (6.5-12.6) | .564 |
| 5-y rate (95% CI) | 76% (58-94) | 68% (62-74) | |
| EFS from start of induction | |||
| Median, years (95% CI) | NR† | 7.9 (5.9-10) | .570 |
| 5-y rate (95% CI) | 70% (51-89) | 65% (59-71) | |
| OS from start of induction | |||
| Median, years (95% CI) | NR† | 13.8 (9.5-18.1) | .443 |
| 5-y rate (95% CI) | 79% (64-94) | 77% (72-82) | |
| TTNT from start of induction | |||
| Median, years (95% CI) | NR† | NR | .918 |
| 5-y rate (95% CI) | 24% (14-36) | 27% (21-33) | |
| Time-to-event outcomes from ASCT | N = 75 | N = 181 | |
| PFS from ASCT | |||
| Median, years (95% CI) | NR† | NR | .095 |
| 5-y rate (95% CI) | 87% (63-100) | 75% (68-82) | |
| EFS from ASCT | |||
| Median, years (95% CI) | NR† | 9.4 (6.9-11.9) | .342 |
| 5-y rate (95% CI) | 79% (56-100) | 73% (66-80) | |
| OS from ASCT | |||
| Median, years (95% CI) | NR† | 13.4 (7.2-19.6) | .137 |
| 5-y rate (95% CI) | 88% (74-100) | 80% (74-86) | |
| TTNT from ASCT | |||
| Median, years (95% CI) | NR† | NR | .373 |
| 5-y rate (95% CI) | 14% (0-35) | 20% (13-26) | |
| . | R-B . | R-CHOP/R-DHAP . | P . |
|---|---|---|---|
| Response rates and additional first line therapies | N = 97 | N = 232 | |
| Response rates after induction, n (%) | |||
| Complete response | 52 (54) | 122/226* (54) | |
| Partial response | 35 (36) | 91/226 (40) | |
| Stable disease | 2 (2) | 5/226 (2) | |
| Progressive disease | 8 (8) | 8/226 (4) | |
| ASCT, n (%) | 75 (77) | 181 (78) | .890 |
| Maintenance rituximab, n (%) | 76 (78) | 4 (2) | <.001 |
| Time-to-event outcomes from start of induction | N = 97 | N = 232 | |
| PFS from start of induction | |||
| Median, years (95% CI) | NR† | 9.5 (6.5-12.6) | .564 |
| 5-y rate (95% CI) | 76% (58-94) | 68% (62-74) | |
| EFS from start of induction | |||
| Median, years (95% CI) | NR† | 7.9 (5.9-10) | .570 |
| 5-y rate (95% CI) | 70% (51-89) | 65% (59-71) | |
| OS from start of induction | |||
| Median, years (95% CI) | NR† | 13.8 (9.5-18.1) | .443 |
| 5-y rate (95% CI) | 79% (64-94) | 77% (72-82) | |
| TTNT from start of induction | |||
| Median, years (95% CI) | NR† | NR | .918 |
| 5-y rate (95% CI) | 24% (14-36) | 27% (21-33) | |
| Time-to-event outcomes from ASCT | N = 75 | N = 181 | |
| PFS from ASCT | |||
| Median, years (95% CI) | NR† | NR | .095 |
| 5-y rate (95% CI) | 87% (63-100) | 75% (68-82) | |
| EFS from ASCT | |||
| Median, years (95% CI) | NR† | 9.4 (6.9-11.9) | .342 |
| 5-y rate (95% CI) | 79% (56-100) | 73% (66-80) | |
| OS from ASCT | |||
| Median, years (95% CI) | NR† | 13.4 (7.2-19.6) | .137 |
| 5-y rate (95% CI) | 88% (74-100) | 80% (74-86) | |
| TTNT from ASCT | |||
| Median, years (95% CI) | NR† | NR | .373 |
| 5-y rate (95% CI) | 14% (0-35) | 20% (13-26) | |